Here we provide statistical code and data for
the paper:
Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W,
Shu, Q, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI,
Cloughesy TF, Nelson SF, Mischel PS (2006) "Analysis of Oncogenic Signaling
Networks in Glioblastoma Identifies ASPM as a Novel Molecular Target", PNAS
| November 14, 2006 | vol. 103 | no. 46 | 17402-17407
Abstract:
Glioblastoma is the most common primary malignant brain tumor of adults and one
of the most lethal of all cancers. Patients with this disease have a median
survival of 15 months from the time of diagnosis despite surgery, radiation and
chemotherapy. New treatment approaches are needed. Recent works suggest that
glioblastoma patients may benefit from molecularly targeted therapies. Here, we
address the compelling need for identification of new molecular targets.
Leveraging global gene expression data from two independent sets of clinical
tumor samples (n=55 and n=65), we identify a gene coexpression module in
glioblastoma that is also present in breast cancer and significantly overlaps
with the ˇ§meta-signatureˇ¨ (MS) for undifferentiated cancer. Studies in an
isogenic model system demonstrate that this module is downstream of the mutant
EGFR receptor, EGFRvIII and that it can be inhibited by the EGFR tyrosine kinase
inhibitor Erlotinib. We identify ASPM (abnormal spindle-like microcephaly
associated) as a key gene within this module and demonstrate its
over-expression in glioblastoma relative to normal brain (or body tissues).
Finally, we show that ASPM inhibition by siRNA-mediated knockdown inhibits tumor
cell proliferation and neural stem cell proliferation, supporting ASPM as a
potential molecular target in glioblastoma. Our weighted gene co-expression
network analysis (WGCNA) provides a blueprint for leveraging genomic data to
identify key control networks and molecular targets for glioblastoma, and the
principle eluted from our work can be applied to other cancers.
Brain cancer (GBM) data network
analysis. The tutorial shows how we constructed our brain cancer networks in 2
independent datasets and how to relate the 2 networks. Contents Part A *) Weighted Brain Cancer Network Construction based on
*8000* most varying genes *) Module Detection involving the 3600 most connected genes *) Gene significance and intramodular connectivity *) Robustness analysis with respect to the soft threshold
beta *) Comparing the results to the unweighted network
construction Microsoft
Word version PDF version Datasets (Zipped) Contents part B (the beginning overlaps with part A) *) Weighted brain cancer network construction based on *3600* most connected genes *) Gene significance and intramodular connectivity in data
sets I and II *) Module Eigengene and its relationship to individual genes *) Regressing survival time on individual gene expression and
the module eigengene Microsoft
Word version PDF version Datasets (Zipped)
Breast Cancer Analysis. This tutorial
shows how to map the Affymetrix U133A probe set IDs into Rosetta chip data. Then
it uses the resulting breast cancer array data to construct a weighted network. Microsoft
Word version PDF Version
Datasets (Zipped)
Cell Line Validation Data. We used dChip
pm-mm normalization on the original Affymmetric Cel files. Rows correspond to
probes, columns to microarrays samples. Dataset (Zipped)
Download the following R function file, which contains several R functions
needed for Weighted Gene Co-Expression Network Analysis. Network
R functions
A
simulated gene co-expression network to illustrate the use of the topological
overlap matrix for module detection